Scilex Holding Company reports developments tied to its non-opioid pain management business, pharmaceutical assets and related healthcare investments. The company acquires, develops and commercializes products for acute and chronic pain, including ZTlido for postherpetic neuralgia, ELYXYB for acute migraine treatment in adults and Gloperba for prophylaxis of gout flares in adults.
Recurring Scilex news also includes material agreements, capital-structure actions, shareholder distributions involving Dream Bowl tokens, intellectual property and litigation counsel matters, strategic investments, clinical or regulatory disclosures, governance updates and operating and financial results.
DataMEDS AI (MEDS) entered an amended non-binding letter of intent to license healthcare technologies and acquire intellectual property and control of Tollo Health. The October 19, 2026 agreement would expand its Datavault AI (DVLT) healthcare license, add an exclusive Data Health Partners license, and acquire QOLPOM intellectual property from EOS and Scilex (SCLX). The assets cover patient goal tracking, biometric medication-delivery verification and wearable-based monitoring of drug effects. DataMEDS would acquire Tollo Health control from HealthBridge Advisors.
The company expects closing in fourth-quarter 2026. A majority of DataMEDS shareholders approved draft definitive agreements, subject to satisfactory management due diligence. Execution remains pending, alongside a fairness opinion, an outstanding-liabilities threshold and Nasdaq requirements, including change-of-control review. Existing third-party licenses limit the proposed Datavault rights.
Scilex Holding (Nasdaq:SCLX) announced that Dream Bowl I Meme Coin tokens begin trading on the Biconomy Exchange on July 6, 2026. Scilex believes trading may enhance liquidity and distribution for stockholders and other eligible equityholders. The company retains approximately 180 million Dream Bowl Tokens after prior distributions.
Biconomy reports serving over 10 million users in 180+ countries, ranking among the top 40 exchanges by volume with about $2.0 billion in average daily trading, and holding 98% of assets in cold storage.
Scilex (Nasdaq:SCLX) signed a binding term sheet with iHolding Group for a proposed $100 million strategic equity investment. iHolding is expected to buy newly issued Scilex common shares at $15.00 per share, or about 6,666,667 shares.
Proceeds would fund growth initiatives, product development, commercialization, acquisitions, partnerships, working capital, and IP expansion. Closing remains subject to due diligence, definitive agreements, board, stockholder, and regulatory approvals.
Oramed (NASDAQ: ORMP) released a shareholder letter detailing portfolio gains, Scilex loan repayments, and upcoming Russell 2000/3000 index inclusion.
Key points include Alpha Tau's value rising to about $167M, Scilex repayments totaling roughly $118M to date, and total cash and assets of about $270M as of March 31, 2026 (unaudited).
Scilex (Nasdaq:SCLX) plans to list its Dream Bowl I Meme Coin tokens on Biconomy Exchange as early as June 23, 2026. The company believes this may provide liquidity and broad distribution for Participating Holders.
Eligible holders receive 5 Dream Bowl Tokens per SCLX share, based on a record date of April 30, 2026, with distributions beginning May 26, 2026. Biconomy reports over 10 million users, average daily volume of about $2.0 billion, and holds 98% of assets in cold storage.
Datavault AI (NASDAQ:DVLT) and Wellgistics Health (NASDAQ:WGRX) signed a fully binding term sheet to form DelivMeds AI (ticker reserved: NASDAQ:MEDS) via three concurrent transactions.
The structure includes a PharmacyChain™ HaaS license expansion, acquisition of QOLPOM biometric and drone logistics IP, and a controlling stake in Tollo Health, with an expected combined asset value of about $4 billion, subject to an independent fairness opinion and customary closing conditions.
Scilex Holding Company (Nasdaq: SCLX) announced that subsidiaries ACEA Therapeutics and ACEA Pharma entered a definitive agreement to sell 100% of ACEA Pharma to Phoenix Asia Holdings (Nasdaq: PHOE) for $1,000,000,000 via 100,000,000 newly issued Phoenix shares at $10.00 per share.
Upon closing, expected by end of Q2 2026 and subject to regulatory and Nasdaq approval, Phoenix will be renamed ACEA Pharma, Inc. and ACEA Thera is expected to own approximately 82% of the Go-Forward Company.
Scilex Holding Company (Nasdaq: SCLX) announced its Board set May 26, 2026 as the payment date for a previously announced dividend of Dream Bowl Meme Coin I tokens to holders of record as of April 30, 2026. Record Holders receive 5 Dream Bowl Tokens per share. Scilex holds ~268 million Dream Bowl Tokens and plans to distribute ~81.4 million. The company intends to list the tokens on Biconomy in Q2 2026. Receipt requires opening a Datavault digital wallet and executing an Opt-In Agreement. The tokens are described as digital collectibles and do not confer equity, voting, dividends, or monetary rights.
Datavault AI (NASDAQ: DVLT) executed a binding term sheet with Scilex for a $120 million cash contribution to fund a 100-city deployment of its quantum-ready SanQtum GPU edge network. The deal ties Scilex to a tiered revenue participation (30% → 15% → 5%) with caps of $250M and $1.2B. Datavault cites existing Nvidia GPUs valued at $1.2 billion and projects a combined $200M+ cash infusion without equity dilution; initial deployments in New York and Philadelphia target Q2 2026 with 100 locations within 36 months.
Scilex Holding Company (Nasdaq: SCLX) announced a dividend of Dream Bowl I meme coin tokens to holders of common stock and other eligible equity securities with a record date of April 30, 2026.
Participating holders will receive 5 Dream Bowl Tokens per share. Scilex holds ~268 million tokens and plans to distribute ~81.4 million. Payment will occur within 60 days after the record date, subject to Board discretion and an opt-in wallet process with Datavault.